Back to Journals » Drug, Healthcare and Patient Safety » Volume 2

Antidepressant-associated sexual dysfunction: impact, effects, and treatment

Authors Higgins A, Nash M, Lynch AM

Published 9 September 2010 Volume 2010:2 Pages 141—150

DOI https://doi.org/10.2147/DHPS.S7634

Review by Single-blind

Peer reviewer comments 3

Agnes Higgins, Michael Nash, Aileen M Lynch
School of Nursing and Midwifery Studies, Trinity College Dublin, Dublin, Ireland

Abstract: Sexual dysfunction is a common side effect of antidepressants and can have significant impact on the person’s quality of life, relationships, mental health, and recovery. The reported incidence of sexual dysfunction associated with antidepressant medication varies considerably between studies, making it difficult to estimate the exact incidence or prevalence. The sexual problems reported range from decreased sexual desire, decreased sexual excitement, diminished or delayed orgasm, to erection or delayed ejaculation problems. There are a number of case reports of sexual side effects, such as priapism, painful ejaculation, penile anesthesia, loss of sensation in the vagina and nipples, persistent genital arousal and nonpuerperal lactation in women. The focus of this article is to explore the incidence, pathophysiology, and treatment of antidepressant iatrogenic sexual dysfunction.

Keywords: depression, antidepressant, iatrogenic sexual dysfunction, SSRI, SNRI

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]

 

Readers of this article also read:

Brodalumab: an evidence-based review of its potential in the treatment of moderate-to-severe psoriasis

Coimbra S, Figueiredo A, Santos-Silva A

Core Evidence 2014, 9:89-97

Published Date: 21 July 2014

Temporomandibular disorders in patients with schizophrenia using antipsychotic agents: a discussion paper

de Araújo AN, do Nascimento MA, de Sena EP, Baptista AF

Drug, Healthcare and Patient Safety 2014, 6:21-27

Published Date: 10 March 2014

An exploratory study on medications in Qatar homes

Kheir N, El Hajj MS, Wilbur K, Kaissi RML, Yousif A

Drug, Healthcare and Patient Safety 2011, 3:99-106

Published Date: 20 December 2011

Antiepileptic drugs and suicidality

Jeffery W Britton, Jerry J Shih

Drug, Healthcare and Patient Safety 2010, 2:181-189

Published Date: 28 September 2010

Clinical safety and tolerability issues in use of triazole derivatives in management of fungal infections

Dionissios Neofytos, Edina Avdic, Anna-Pelagia Magiorakos

Drug, Healthcare and Patient Safety 2010, 2:27-38

Published Date: 20 April 2010